Royal Bank of Canada
OBIO icon

Royal Bank of Canada’s Orchestra BioMed OBIO Stock Holding History

Royal Bank of Canada’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4K Buy
936
+565
+152% +$2.4K ﹤0.01% 6507
2025
Q4 		$1K Sell
371
-5,992
-94% -$24.2K ﹤0.01% 7027
2025
Q3 		$16K Sell
6,363
-1,466
-19% -$4.04K ﹤0.01% 6315
2025
Q2 		$21K Buy
7,829
+7,215
+1,175% +$21.1K ﹤0.01% 6246
2025
Q1 		$3K Sell
614
-3,450
-85% -$17.2K ﹤0.01% 6511
2024
Q4 		$16K Buy
4,064
+1,251
+44% +$6.72K ﹤0.01% 6204
2024
Q3 		$14K Buy
2,813
+528
+23% +$3.45K ﹤0.01% 6231
2024
Q2 		$19K Buy
2,285
+1,621
+244% +$9.39K ﹤0.01% 6097
2024
Q1 		$4K Sell
664
-4,595
-87% -$31.1K ﹤0.01% 6519
2023
Q4 		$48K Buy
5,259
+3,266
+164% +$22.3K ﹤0.01% 6012
2023
Q3 		$17K Buy
1,993
+1,477
+286% +$9.93K ﹤0.01% 6236
2023
Q2 		$4K Buy
+516
New +$7.83K ﹤0.01% 6743

Other funds holding OBIO

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Royal Bank of Canada's OBIO Position: Q1 2026 in Review

Royal Bank of Canada increased its Orchestra BioMed (OBIO) stake by 152% in Q1 2026, buying an estimated $2.4K and bringing the position to 936 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #6507.

Royal Bank of Canada first reported a position in OBIO in Q2 2023 and has held it in 12 quarters since. The position peaked at $48K in Q4 2023. 65 funds tracked by Wall St. Rank hold OBIO as of Q1 2026.

  • Royal Bank of Canada held 936 shares of Orchestra BioMed worth $4K as of Q1 2026.
  • Royal Bank of Canada bought 565 Orchestra BioMed shares in Q1 2026, an estimated $2.4K.
  • Orchestra BioMed made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6507 holding.
  • Royal Bank of Canada first reported a position in Orchestra BioMed in Q2 2023 and has held it in 12 quarters since.
  • Royal Bank of Canada's Orchestra BioMed position peaked at $48K in Q4 2023.
  • 65 funds tracked by Wall St. Rank held Orchestra BioMed as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.